# Gilead's herpes deal; FDA approvals for Boehringer, Roche

**Source:** Endpoints News
**URL:** https://e.endpointsnews.com/t/t-l-wojdx-jykykhhuld-h/
**Date:** 2025-12-29

---

CHANNELS WEBINARS SIGNAL MORE

LOG IN

December 23, 2025 09:46 AM EST News Briefing

GileadÂ­'s herÂ­pes deal; FDA apÂ­provals for Boehringer, Roche

ENDPOINTS

Plus, news about BioÂ­Marin and CasÂ­saÂ­va.

ğŸ’Š Gilead opts inÂ­to AsÂ­semÂ­bly Bioâ€™s genÂ­iÂ­tal herÂ­pes proÂ­grams: As a reÂ­sult, Gilead will pay AsÂ­semÂ­bly $35 milÂ­lion based â€¦

MORE LIKE THIS

AlÂ­timÂ­mune adÂ­vances in MASH; New ChiÂ­na obeÂ­siÂ­ty biotech; Ipsen Phase 2 fail

December 19, 2025

SubÂ­cuÂ­taÂ­neous RyÂ­breÂ­vant; Kalaris shares nAMD daÂ­ta; PyxÂ­is disÂ­apÂ­points

December 18, 2025

Vir liÂ­censÂ­ing deal; CyÂ­toÂ­kiÂ­netÂ­ics wins ChiÂ­na nod; VistaÂ­gen's soÂ­cial anxÂ­iÂ­ety fail

December 17, 2025

TRENDING NOW

J&J axÂ­es eczema drug from $1.25B acÂ­quiÂ­siÂ­tion

NoÂ­vo Nordisk eyes a strong launch with FDA apÂ­proval of obeÂ­siÂ­ty pill

UpÂ­datÂ­ed: PfizÂ­er disÂ­closÂ­es paÂ­tient death in HymÂ­paÂ­vzi heÂ­moÂ­philÂ­ia triÂ­al

DrugÂ­makÂ­ers with White House MFN deals claim exÂ­empÂ­tion from proÂ­posed Medicare pricÂ­ing tests

CMS unÂ­veils Medicare covÂ­erÂ­age modÂ­el for weight loss drugs

The EndÂ­points winÂ­ners and losers list: Who was up and who was down in 2025

Bioscience & Technology Business Center

The University of Kansas

Lawrence, Kansas

latest

All News

Special

In Focus

channels

AI

Bioregnum

Biotech Voices

Cell/Gene Tx

China

Coronavirus

Deals

Diagnostics

Discovery

FDA+

Financing

Health Tech

Law

Letters to the Editor

Manufacturing

Marketing

Nikkei Biotechnology

Opinion

Outsourcing

Peer Review

People

Pharma

R&D

Startups

Weekly

more

Work at Endpoints

Letter to Editors

Editorial Standards

IPO Tracker

Events

Webinars

Sponsored Posts

Advertise

Endpoints Merch

About Us

Help

work in biotech

Endpoints Careers

Â© Endpoints News 2025

---

#news #endpoints-news
